載入中
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
前收盤價
US$1.60
+US$0.12 · +8.11%
盤中時間採用ET。市場資料可能有所延遲。
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
日內區間
目前US$1.60
52週區間
目前US$1.60
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
53
合理估值
情緒
60
多空交錯
風險
62
高風險
動能
72
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
日內區間
目前US$1.60
52週區間
目前US$1.60
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 91.7萬 USD | 63.7萬 USD | 27.9萬 USD | 41萬 USD | 80.2萬 USD |
| 銷貨成本 | 42.2萬 USD | 15.4萬 USD | — | — | 7萬 USD |
| 毛利 | 49.5萬 USD | 48.3萬 USD | 27.9萬 USD | 41萬 USD | 80.2萬 USD |
| 研究與開發 | 1282.3萬 USD | 9403.1萬 USD | 631.2萬 USD | 874.2萬 USD | 490.7萬 USD |
| 銷售、一般及管理費用 | 1378.1萬 USD | 885.4萬 USD | 893.2萬 USD | 1697.8萬 USD | 2041.6萬 USD |
| 營業費用 | 2660.4萬 USD | 1.03億 USD | 1532.2萬 USD | 6088.7萬 USD | 2900.1萬 USD |
| 利息收入 | 199.6萬 USD | 238.3萬 USD | 325.3萬 USD | 20.1萬 USD | 2000 USD |
| 利息支出 | 65.8萬 USD | 24.8萬 USD | — | 6000 USD | 1.2萬 USD |
| 折舊和攤銷 | 28.8萬 USD | 22.5萬 USD | 7.8萬 USD | 7.2萬 USD | 7萬 USD |
| 營業利益 | −2610.9萬 USD | −1.03億 USD | −1504.3萬 USD | −6047.7萬 USD | −2119.9萬 USD |
| 淨利 | −3052萬 USD | −3441萬 USD | −187.6萬 USD | −1.25億 USD | −2454.4萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2009年12月18日 | US$0.02Semi-Annual | — | 2009年12月31日 |
股息 | 2009年6月19日 | US$0.02Semi-Annual | — | 2009年6月30日 |
除息 2009年12月18日
US$0.02
Semi-Annual
支付日 2009年12月31日
除息 2009年6月19日
US$0.02
Semi-Annual
支付日 2009年6月30日
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI250.74萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF121.93萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC15.47萬0.01%13.17億 USD0.60%US$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC13.72萬0.00%75.58億 USD0.43%US$57.813+0.20%
Dimensional - US Small Cap ETFDFAS6.63萬0.00%338.69億 USD0.31%US$78.35+0.32%
Dimensional - US Core Equity 2 ETFDFAC5.39萬0.00%885.96億 USD0.21%US$45.33+0.49%
U.S. Vector Equity Portfolio ETF Class SharesDXUV3.55萬0.00%61.81億 USD0.26%US$68.28+0.25%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR2.92萬0.00%455.91億 USD0.17%US$84.44+0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Core Equity 2 ETFDFACU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
